Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.14
EPS est.
$-0.23
EPS surprise
+38.60%
1-day move
-3.92%
The earnings report shows that 10x Genomics is experiencing growth in its core revenue and strong demand for its Atera platform. However, the stock fell by nearly 4% likely due to concerns about a potential revenue decline in the upcoming quarter as customers adjust their purchasing habits. Investors will be watching closely to see how the company navigates this transition.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | +38.60% |
| Revenue | $151 million | N/A | N/A |
| Core Revenue | $149 million | N/A | N/A |
| Total Consumables Revenue Growth | 7% | N/A | N/A |
| Single-Cell Consumables Growth | 3% | N/A | N/A |
| Spatial Consumables Growth | 16% | N/A | N/A |
Management expressed cautious optimism about the strong demand for the Atera platform, which has led to an increase in full-year revenue guidance. However, they noted that Q3 may see a modest sequential revenue decline as customers adjust their purchasing behavior.
Strong demand for the Atera platform has led to raised full-year revenue guidance.
Initial customer reception for Atera has exceeded expectations.
10x Genomics, Inc. is a healthcare company specializing in life sciences tools and services. They focus on advanced genomic technologies that help researchers and clinicians better understand biological systems and diseases, making their work crucial in the fields of genomics and personalized medicine.
Last quarter
In Q1-2026, 10x Genomics reported an EPS of -$0.10, which was a positive surprise compared to the expectation of -$0.29. Despite this, the stock fell 1.41% the following day, indicating mixed investor sentiment.
Management promises and guidance
EPS beat streak
6Q
EPS beat rate
88%
Avg EPS surprise
+44.72%
Avg 1-day reaction
-1.44%
Overall, expectations are mixed as the company has a history of beating EPS estimates but has struggled with stock performance following earnings announcements.
Bull case
If 10x Genomics can deliver strong revenue growth and maintain or improve their EPS, it could signal a robust recovery and growth trajectory, attracting more investors.
Bear case
Conversely, if the company fails to meet revenue expectations or shows signs of stagnation, it could lead to further declines in stock price, especially given the high implied volatility.
The print will turn on these.
Q1
What will be the EPS for Q2-2026?
Given the company's history of EPS surprises, this number will be crucial in determining investor sentiment and stock movement.
Q2
How is revenue growth trending compared to previous quarters?
Investors will closely watch revenue growth as it indicates the company's ability to scale and attract new customers.
—
Est. EPS
$0.31
Est. Rev
$300M
Impl. Move
±34.2%
Why consensus could be wrong
The Street may be underestimating the potential for significant revenue growth due to new product launches that have not been fully accounted for in current estimates.
Supporting evidence
The company has a strong track record of beating EPS estimates, suggesting they may outperform again.
Options pricing indicates high volatility, which could reflect investor uncertainty not captured in consensus estimates.
Key risk
If revenue growth exceeds expectations, it could shift the narrative around the company's growth potential.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will reveal whether the company can sustain its growth momentum and profitability amidst market pressures.
Bull confirmed if
Achieving an EPS of $0.00 or better would confirm the bull case and indicate a turnaround in profitability.
Bear confirmed if
An EPS of -$0.20 or worse would confirm the bear case, suggesting ongoing challenges in profitability.
What the market is pricing for the move.
Implied Move
±30.91%
Historical Avg
±3.1%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±30.9% while TXG has averaged ±3.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
69.6%
Smart-money positioning from the most recent 13F filings.
Institutional
120.32%
of float
Insider
1.44%
of float
Holders
524
institutions
Top Holders· as of Jun 2026
FMR, LLC
17,629,266 sh · $1.3B
14.67%
-0.6%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If 10x Genomics beats expectations, history suggests the stock could see a modest increase of around 3.2%, confirming a positive outlook.
In line / cautious
If results are in line with expectations but management provides cautious commentary, the stock may experience muted movement as investors reassess.
Miss
Should the company miss expectations, history indicates a potential decline of around 1.5%, reflecting investor disappointment.
The lines on the call that would change the story.
Blackrock Inc.
10,804,070 sh · $822.2M
8.99%
7.2%
ARK Investment Management, LLC
10,003,057 sh · $761.2M
8.32%
-14.6%
Vanguard Portfolio Management LLC
6,982,492 sh · $531.4M
5.81%
1.0%
Quantinno Capital Management, LP
5,469,698 sh · $416.2M
4.55%
1.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.